Nanexa AB (SE:NANEXA)

:NANEXA

NANEXA

Nanexa AB

RESEARCH TOOLSreports

Want to see SE:NANEXA full AI Analyst Report?

Nanexa AB (NANEXA) Price & Analysis

0 Followers

NANEXA Stock Chart & Stats

kr3.03

kr0.05(3.79%)

At close: Mar 06 4:00 PM EST

kr3.03

kr0.05(3.79%)

Day’s Range― - ―

52-Week Rangekr1.40 - kr5.00

Previous CloseN/A

Volume242.80K

Average Volume (3M)266.98K

Market Cap

kr734.87M

Enterprise Valuekr660.75M

Total Cash (Recent Filing)kr73.02M

Total Debt (Recent Filing)kr987.00K

Price to Earnings (P/E)―

Beta0.12

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding164,585,050

10 Day Avg. Volume346,691

30 Day Avg. Volume266,979

Financial Highlights & Ratios

PEG Ratio1.02

Price to Book (P/B)6.83

Price to Sales (P/S)19.19

P/FCF Ratio-26.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr112.20M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetVery low debt relative to equity gives Nanexa financial flexibility through long development cycles and reduces refinancing risk. This durable strength supports continued R&D and partnership negotiations without immediate pressure to monetize assets or accept unfavorable deal terms.

Partnership- And Licensing-driven ModelA licensing and partnership model creates multiple non-dilutive revenue channels (upfronts, R&D fees, milestones, royalties). This structure scales with partner investments, limits commercial capex needs, and aligns incentives with pharma customers, supporting durable, contract-linked cash flow potential.

Proprietary PharmaShell Long-acting PlatformA differentiated long-acting depot platform addresses a structural industry trend toward extended‑release biologics and adherence improvements. Proprietary formulation tech can create a competitive moat, attract partners seeking lifecycle and route-of-administration advantages, and sustain licensing demand.

Bears Say

Deep Negative Free Cash FlowSubstantial negative free cash flow is a persistent structural weakness that forces reliance on external funding or partner payments. It raises dilution and execution risk, constrains the ability to advance internal programs independently, and limits flexibility for larger commercial investments.

Ongoing Operating Losses & Weak MarginsLarge negative margins reflect significant ongoing R&D and development spending. While losses have narrowed, sustained negative operating results challenge the path to self-funded growth and increase dependence on milestone deals or capital raises to reach durable profitability.

Modest, Volatile Revenue BaseA small and slightly declining revenue base reduces cash visibility and negotiating leverage with partners. Revenue volatility makes milestone timing critical to funding, heightens execution risk for multi-year projects, and limits demonstrated commercial traction for the PharmaShell platform.

Nanexa AB News

Nanexa AB’s Phase 1 Study on NEX-22A: A Potential Game-Changer for Diabetes Treatment?

Nanexa AB (($DE:40M)) announced an update on their ongoing clinical study. Study Overview: The recent clinical study by...

9M ago

40M

NANEXA FAQ

What was Nanexa AB’s price range in the past 12 months?

Nanexa AB lowest stock price was kr1.40 and its highest was kr5.00 in the past 12 months.

What is Nanexa AB’s market cap?

Nanexa AB’s market cap is kr734.87M.

When is Nanexa AB’s upcoming earnings report date?

Nanexa AB’s upcoming earnings report date is Aug 27, 2026 which is in 73 days.

How were Nanexa AB’s earnings last quarter?

Nanexa AB released its earnings results on Apr 29, 2026. The company reported -kr0.082 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.082.

Is Nanexa AB overvalued?

According to Wall Street analysts Nanexa AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nanexa AB pay dividends?

Nanexa AB does not currently pay dividends.

What is Nanexa AB’s EPS estimate?

Nanexa AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nanexa AB have?

Nanexa AB has 164,585,050 shares outstanding.

What happened to Nanexa AB’s price movement after its last earnings report?

Nanexa AB reported an EPS of -kr0.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.904%.

Which hedge fund is a major shareholder of Nanexa AB?

Currently, no hedge funds are holding shares in SE:NANEXA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nanexa AB

Nanexa AB (publ) is a firm dedicated to developing advanced drug delivery solutions through nanotechnology. The company leverages its proprietary PharmaShell platform, a nanobased system that utilizes atomic layer deposition (ALD) technology for drug administration. Furthermore, Nanexa is progressing NEX-18, a PharmaShell-based candidate specifically designed to address severe conditions such as Myelodysplastic Syndrome and Acute Myeloid Leukemia. The company was established in 2007 and is headquartered in Uppsala, Sweden.